Sperm Count and Microbial Metabolites

May 23, 2026 ·

Thaena Inc.

I - The Rabbit Hole That Started This Episode

This piece started with a different paper. A 2020 randomized clinical trial by Helli and colleagues, published in Human Fertility, titled "Probiotic effects on sperm parameters, oxidative stress index, inflammatory factors and sex hormones in infertile men." It was a clean-looking study. Multi-strain probiotic, double-blind design, 52 men with idiopathic oligoasthenoteratozoospermia, ten weeks of intervention. It reported that the probiotic significantly improved sperm concentration and motility, raised total antioxidant capacity, and lowered inflammatory markers like CRP and TNF-alpha. The findings were positive across the board. The paper went on to be cited in at least four subsequent systematic reviews and meta-analyses as positive evidence for the probiotic-to-sperm pathway.

On April 28, 2026, it was retracted.

I want to be careful here, because the retraction notice does not specify the reason. I am not making a claim about the original authors. What I am saying is that this paper was load-bearing for a particular pop-science conclusion, the conclusion that taking a probiotic supplement can improve sperm parameters, and now it is gone, and the conclusion has to be re-examined. The systematic reviews that included Helli are still online. The press coverage citing it is still online. Retractions do not unring the bell.

But the question the paper was asking is still a really good question. The hypothesis Helli and colleagues were testing was reasonable: if oxidative stress in the male reproductive tract impairs sperm parameters, and if the gut microbiome modulates systemic oxidative stress, then an intervention with antioxidant effects through the microbiome should improve sperm parameters. The logic is clean. The biomarkers they chose are still the right biomarkers. The design wasn't wrong. What got retracted was a single trial, not the underlying mechanistic biology.

Three pieces of primary research, all independent of Helli, support the underlying biology this article walks through. A 2026 rat study from Liu and colleagues in the Journal of Nanobiotechnology demonstrated, via fecal microbiota transplant, that gut dysbiosis can causally produce testicular damage. A 2026 mouse study from Wang and colleagues in Communications Biology identified a specific gut-microbial tryptophan metabolite, kynurenic acid, as sufficient to impair spermatogenesis. And a 2025 cohort study in Human Reproduction by Priskorn and colleagues, following 78,284 Danish men for up to 50 years, found a dose-response relationship between semen quality and all-cause mortality, with oxidative stress proposed as the unifying upstream mechanism in the accompanying Aitken editorial.

So the rabbit hole opened with a retracted paper and closed with a more honest picture: the connection between gut microbiome, oxidative stress, and sperm quality is real, supported by mechanism work in animals and large-scale human epidemiology. The simple "take a probiotic" intervention does not have the evidence we would want, and the most-cited recent attempt to provide that evidence got pulled. The interesting work is happening at the metabolite layer. Which is what the rest of this article walks through, starting with a comprehensive 2026 review that arrives at the same conclusion.

II - The Paper That Refuses to Overclaim

A paper in the FASEB Journal made me put my coffee down this week. It was not because of what it claimed. It was because of what it refused to claim.

The paper is Skrabulyte-Barbulescu and colleagues, 2026, "Innate Immunity and Microbial Recognition in Reproduction: From Barrier Defense to Maternal-Fetal Tolerance." It is a comprehensive review of how the immune system, the microbiome, and reproductive tissues talk to each other. And it keeps stopping itself to say: hold on, the evidence in this niche is shaky. The samples in this compartment are easy to contaminate. The associations we keep finding might actually be associations with inflammation, not with the bacteria themselves.

That kind of methodological restraint is rare in review papers, which usually want to tell a clean story. This one chooses honesty over neatness. And buried in its careful prose is one of the most important reframes in microbiome science today.

III - What the FASEB Authors Actually Studied

The Skrabulyte-Barbulescu review pulls together evidence from epithelial biology, immunology, microbial ecology, and reproductive physiology to map how innate immunity manages two opposing tasks at once: blocking pathogens while tolerating gametes and, during pregnancy, a semi-allogeneic conceptus. The review covers female and male reproductive tracts as well as the maternal-fetal interface, and it pays close attention to the role of microbiota and microbial metabolites in shaping immune tone in those tissues.

The central conceptual contribution is what the authors call a "unified barrier defense and tolerance framework." Innate immune sensing, barrier architecture, microbial ecology, and endocrine and metabolic context are functionally coupled. When the system works, gametes get through, pathogens get blocked, and inflammation stays controlled. When it fails, you get the spectrum of reproductive disorders the paper catalogs: infertility, recurrent pregnancy loss, preterm birth, sperm dysfunction.

IV - Are Gut-Derived Metabolites the Real Active Ingredient?

The sentence I underlined twice on first read is this:

Gut-derived metabolites emerge as important regulators of immune tone and barrier function in reproductive tissues. Skrabulyte-Barbulescu et al., FASEB Journal, 2026

That single line is doing a lot of work. The authors are saying that the molecules your gut bacteria produce are shaping how your reproductive tissues regulate inflammation. Not the bacteria themselves. The molecules they make. The review goes through the specific classes: short-chain fatty acids, which gut bacteria make when they ferment fiber. Bile acids, which get chemically modified by bacterial enzymes as they cycle through your gut. Tryptophan derivatives like indoles, kynurenic acid, and indole-3-propionic acid. All of these reach immune cells and epithelial cells far from the gut and tune their behavior.

The authors are also careful to distinguish what evidence is strong from what evidence is shakier. Cervicovaginal microbiome science has large, reproducible datasets behind it. Male genital microbiota work, by contrast, suffers from low-biomass sampling, contamination risk, and inconsistent methods. The review delivers a particularly important caveat in plain language:

V - Why Probiotic-to-Sperm-Count Trials Keep Disappointing

If the microbiome is connected to reproductive health, the obvious move is to take a probiotic. The honest answer is the field is messier than the marketing.

A widely cited 2022 randomized clinical trial by Helli and colleagues, "Probiotic effects on sperm parameters, oxidative stress index, inflammatory factors and sex hormones in infertile men," was retracted by the journal Human Fertility on April 28, 2026. The original paper had reported that a multi-strain Lactobacillus and Bifidobacterium probiotic improved sperm parameters, raised antioxidant capacity, and lowered inflammatory markers in men with infertility. It made it into at least four subsequent systematic reviews and meta-analyses as positive evidence for the probiotic-to-sperm pathway. It also made its way into news roundups and wellness press as a quotable result.

I want to be careful here. The retraction notice itself does not specify the reason for the retraction, so I am not making a claim about the original authors. What I am saying is that this paper was load-bearing for a particular pop-science conclusion, and the meta-analyses that included it now need a sensitivity analysis without it. Retractions do not unring the bell. The systematic reviews are still online. The press coverage citing them is still online.

The retraction is not isolated. It is one visible example of a broader pattern that has been quietly building in the probiotic literature for years.

VI - Seven Barriers to Probiotic Translation

When a probiotic intervention does not reliably translate from a single positive trial to a robust therapeutic, the reasons usually fall into one of seven categories. Each of these is real, well-documented, and compounds with the others.

Read together, these barriers explain why the probiotic field has produced a steady stream of promising single trials and very few robust therapeutic translations. They also explain why the FASEB authors are quietly arguing for a different approach.

VII - What Postbiotics Actually Are (And How They Differ From Probiotics)

Before going further, a definitional pause. The terms in this space are used loosely enough that they cause real confusion.

Probiotics are live microorganisms intended to confer a health benefit when consumed in adequate amounts. They are alive at the time of administration. The benefit is supposed to come from the bacteria themselves, either by colonizing the host, by interacting with the existing microbiota, or by producing molecules in situ.

Prebiotics are substrates (mostly fibers and certain polyphenols) that selectively feed beneficial gut bacteria. They are not microbes themselves. They are food for microbes.

Postbiotics are the bioactive molecules produced by microbes and the non-viable microbial components that retain biological activity. The International Scientific Association for Probiotics and Prebiotics defined postbiotics in 2021 as "a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host." The category includes short-chain fatty acids, bacterial cell wall fragments, exopolysaccharides, modified bile acids, and the broader chemical output of the microbiome.

The shift from probiotics to postbiotics is not just terminological. It is a shift in what we think the active ingredient is. The probiotic model assumes the bacteria are doing the work. The postbiotic model assumes the molecules the bacteria make are doing the work. Most of the seven translation barriers above either disappear or shrink dramatically under the postbiotic model. You can standardize molecules. You cannot easily standardize a living ecosystem inside a capsule.

VIII - The Mechanism: SCFAs, Bile Acids, Indoles, and the Nrf2 Pathway

A 2025 review my team published in the Journal of Restorative Medicine, "Balancing Oxidative Stress: How the Gut Microbiome Supports Redox Homeostasis and Mitochondrial Health" (McBeth et al., 2025), walked through the specific mechanism by which gut metabolites support antioxidant defense throughout the body. The FASEB review and our own work are pointing at the same architecture from different angles.

The central pathway is called Nrf2 and ARE. Nrf2, short for nuclear factor erythroid 2-related factor 2, is a transcription factor that lives in cells in a normally suppressed state. When activated, it translocates to the nucleus and binds to DNA sequences called antioxidant response elements (AREs). These AREs sit upstream of the genes that code for the body's antioxidant enzymes: superoxide dismutase, catalase, glutathione peroxidase, and many others. When Nrf2 lights up the AREs, the cell makes more antioxidant machinery. This is not a small system. It is the master switch for endogenous antioxidant defense.

A surprisingly broad list of gut-derived metabolites activates this pathway. Short-chain fatty acids like butyrate signal through G-protein-coupled receptors (GPR43, GPR109a) and through histone deacetylase inhibition, both of which feed into Nrf2 activation. Secondary bile acids produced by bacterial dehydroxylation, like ursodeoxycholic acid and taurursodeoxycholic acid, have direct antioxidant signaling effects. Tryptophan derivatives like indole-3-propionic acid and indole-3-acetic acid cross the blood-brain barrier and activate antioxidant defense in tissues including the brain. These molecules are not just markers of a healthy microbiome. They are functional signals that wake up the body's own protective machinery.

IX - The FASEB Reframe: Network-Based Over Single-Target

Here is the heart of the FASEB paper, in the authors' own words:

This systems perspective argues against overly reductionist single-target models and instead supports network-based interventions that restore barrier integrity, microbial balance, and immune resolution together. Skrabulyte-Barbulescu et al., FASEB Journal, 2026

The reason single-strain probiotic interventions keep being disappointing, in this framing, is because they are trying to fix a network with a single ingredient. The reproductive immune system, the gut microbiome, the metabolite layer connecting them: this is a system. Systems do not usually respond to single-target interventions the way drugs respond to single targets. Systems respond to network interventions, things that change the whole metabolic and inflammatory context at once.

The authors are not advocating for any specific product or class of intervention. They are making a methodological point. And that point happens to be where the postbiotic argument lives. A full-spectrum postbiotic captures two things no single-strain probiotic can: the emergent chemistry that only appears in a functional community, and the metabolic context that lets the body's resident microbes do their work. We believe this is a plausible mechanism. It is a thesis, not a proven clinical outcome. The human trial data needed to validate it is part of what Thaena is working toward.

X - Why Sperm Count Is a Sensitive Proxy for Systemic Oxidative Stress

Sperm cells are uniquely vulnerable to oxidative damage. Three biological features compound the vulnerability. First, sperm have very little cytoplasm, which means they have very little cytoplasmic antioxidant reserve to neutralize reactive oxygen species. Second, their membranes are loaded with polyunsaturated fatty acids that are especially susceptible to lipid peroxidation. Third, during their journey through the male reproductive tract, they are exposed to oxidative stress from multiple sources, including from white blood cells in the semen itself.

That vulnerability makes sperm count a sensitive output of systemic oxidative balance. A 2025 paper in Human Reproduction by Priskorn and colleagues followed 78,284 men in Denmark for up to 50 years and found a dose-response relationship between sperm quality and all-cause mortality. Men with total motile sperm counts above 120 million had a life expectancy of 80.3 years. Men with total motile sperm counts under 5 million had a life expectancy of 77.6 years. The difference held after adjustment for education and prior disease, which means it was not explained by social determinants or by visible illness at the time of sperm assessment.

The accompanying editorial by Aitken proposed oxidative stress as the unifying mechanism. Reactive oxygen species damage sperm DNA, lipids, and membrane integrity. The same reactive oxygen species drive cellular senescence, mitochondrial dysfunction, and chronic inflammation in tissues throughout the body. Whatever is grinding down sperm cells is probably also grinding down the rest of you. Sperm count, in this framing, is less a fertility metric and more an aging biomarker. The canary in the coal mine for systemic oxidative load.

I want to be careful here, because I do not want anyone to walk away from this thinking they need to track or worry about sperm count. That is not the point. The point is that the biology that protects reproductive cells from oxidative damage is the same biology that protects everything else. That biology is partly regulated by what your microbiome is producing. Sperm count is one measurable proxy for a story that applies to everyone, not just to half the population.

XI - What a Real Test of This Thesis Would Look Like

If the FASEB authors are correct that gut-derived metabolites regulate immune tone and barrier function in tissues throughout the body, and if our own work is correct that those same metabolites activate Nrf2 and the broader antioxidant response, then the cleanest way to test the thesis is to find a population where the system is visibly under load and ask whether supporting the metabolite layer changes a measurable downstream output.

The population that keeps surfacing in this literature is men with chronic low-grade gut symptoms, often described under the irritable bowel syndrome umbrella. IBS-spectrum gut symptoms affect roughly 10 to 15 percent of US adults and are consistently associated with altered microbiome composition, reduced microbial metabolic diversity, and elevated markers of systemic inflammation and oxidative stress. This population is not a disease cohort. It is a high-noise-signal cohort: the system is visibly under load, but the load is broadly distributed across the population. That is exactly the kind of group where a network-level intervention is most likely to produce a measurable signal.

The measurable downstream output worth tracking, given everything above, is sperm count. Not because the study is about fertility. Because sperm count is unusually cheap, unusually quantitative, and unusually sensitive to systemic oxidative load. A pre and post within-subject comparison with a long enough intervention window (the antioxidant meta-analysis literature suggests longer than six months is more informative than shorter than three) could in principle detect whether supporting the gut metabolite layer changes a biomarker that has been independently linked to systemic oxidative balance and all-cause mortality.

The intervention vehicle that would test this most directly is a full-spectrum postbiotic, not a single-strain probiotic. The reasons trace back to the seven barriers above: a postbiotic preparation delivers the metabolite layer directly, sidestepping strain specificity, engraftment failure, and the mechanism opacity that has made probiotic trials so hard to interpret. A full-spectrum postbiotic in this population, with sperm count as the primary outcome and standard inflammation and oxidative stress markers as secondary outcomes, would be the most precise test of the metabolite-first thesis we have at our disposal.

To be clear about what this is and is not: it is a research design proposal grounded in the mechanistic and epidemiologic evidence above. It is not a claim that the trial would produce a positive result. The trial has not been run. The hypothesis is plausible enough to test and not yet proven enough to assert. That is exactly the position where good science begins.

XII - What This Means for Your Daily Choices

This particular paper focuses on sperm count as a measurable proxy because it is one of the cheapest and most sensitive available outputs of systemic oxidative load. The same underlying biology applies to everyone, and future research will use different measurable outputs in different populations.

The boring honest answer is that supporting a healthy gut metabolite output is mostly the things you have already heard, but they are true.

Eat a wide diversity of plant foods. Fiber and polyphenols are the substrates your gut bacteria need to make the metabolites that activate antioxidant defense. The diversity matters as much as the quantity. Different fibers feed different bacterial species.

Protect your sleep and circadian rhythm. Recent mechanistic work has shown that circadian disruption directly changes gut metabolite production. The microbiome operates on a daily clock, and so does the metabolite output the rest of your body depends on.

Limit the well-documented oxidative stress amplifiers. Smoking, heavy alcohol use, chronic cannabis use, ultra-processed food, and chronic sleep deprivation are all documented oxidative stress drivers. Each loads the system on the wrong side of the balance.

Be skeptical of bold probiotic claims. Not because probiotics are bad. Because the field is genuinely noisy. If you take a probiotic and it makes you feel better, that is fine, keep doing what works for you. But do not expect any particular probiotic to deliver on a specific systemic claim with the evidence you would want from any other intervention.

Watch the postbiotic field. This is where the science is moving. The FASEB authors are calling for it. The mechanistic literature is converging on it. Over the next several years, the most rigorous clinical evidence in microbiome-related health is likely to come from the metabolite layer.

XIII - What to Watch in the Field

Three threads worth tracking over the next 12 to 24 months.

1. Network-based intervention trials. The FASEB authors are not the only voices calling for this shift. Watch for clinical trials that intervene at the level of metabolite supplementation, multi-target dietary protocols, or full-spectrum microbial preparations rather than single-strain probiotics. These designs are harder and more expensive, but they reflect how the biology actually works.

2. Continued retraction and reassessment in the probiotic literature. The Helli 2022 retraction is unlikely to be the last. As more of the field is subjected to careful methodological audit, expect more reassessments of single-strain RCT data that supported earlier confident claims.

3. Metabolomic biomarkers for microbiome function. The most useful microbiome assessments are increasingly metabolomic rather than taxonomic. Measuring the molecules a microbiome is actually producing tells you more about function than counting which species are present. This is changing how research groups design studies, and it is starting to change clinical thinking too.

XIV - Frequently Asked Questions

Do probiotics actually improve sperm count?

The evidence is much messier than it looks. Several small randomized trials have reported positive effects from specific multi-strain probiotics, but one of the most cited (Helli et al., 2020) was retracted in April 2026. The broader literature suffers from strain specificity, engraftment failure, and mechanism opacity. The most honest answer is that no probiotic on the market today has the kind of robust, replicated, mechanistic evidence we would expect from any other systemic health intervention.

Why does this article keep mentioning a retracted paper?

Because the retraction itself is part of the honest story. The 2020 Helli paper was load-bearing for the "probiotics improve sperm count" pop-science conclusion across at least four systematic reviews. When it was retracted in April 2026, that conclusion lost its primary support. The retraction does not undermine the underlying biology, which is supported by independent primary research in rats, mice, and a 78,000-person human cohort. It does undermine the specific claim that taking a probiotic supplement is a validated intervention. Naming the retraction explicitly is how we keep the science honest.

What is the difference between probiotics, prebiotics, and postbiotics?

Probiotics are live microorganisms. Prebiotics are substrates (mostly fibers) that feed beneficial gut bacteria. Postbiotics are the inanimate microbial components and metabolites that confer biological activity, defined by ISAPP in 2021. The shift from probiotics to postbiotics reflects a shift in what we think the active ingredient is: bacteria versus the molecules they produce.

Is sperm count actually a biomarker of general health?

A 2025 Danish cohort of 78,284 men found a dose-response association between sperm quality and all-cause mortality (Priskorn et al., 2025). The accompanying editorial proposed oxidative stress as the unifying upstream mechanism (Aitken, 2025). The biological logic is that sperm cells have unusually low antioxidant reserves and are therefore sensitive to systemic oxidative load, which also drives broader cellular aging.

What does the FASEB paper recommend instead of taking probiotics?

The Skrabulyte-Barbulescu review does not recommend a specific product. It argues against reductionist single-target models in favor of network-based interventions that restore barrier integrity, microbial balance, and immune resolution together. The practical translation, for now, is supporting a healthy gut metabolite output through diet diversity, sleep, and limiting documented oxidative stress amplifiers.

Why is the male genital microbiome research so cautious in this review?

The samples are low-biomass, which makes them especially vulnerable to reagent contamination, collection-method bias, and inconsistent bioinformatic filtering. The FASEB authors note that "current male genital microbiota data are stronger as associative markers of inflammatory or oxidative stress states than as proof of a conserved resident microbiota with uniform effects on fertility." In plain language: the bacterial signals may be flagging inflammation rather than causing it.

What is the Nrf2 pathway and why does it matter?

Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that activates the genes coding for the body's antioxidant enzymes when triggered. It is one of the master regulators of endogenous antioxidant defense. Short-chain fatty acids, modified bile acids, and tryptophan derivatives produced by gut bacteria all converge on activating this pathway (McBeth et al., 2025), which is part of how the microbiome supports systemic redox balance.

What kind of study would actually test whether a postbiotic supports systemic oxidative balance?

The most precise available test would be a within-subject pre-post study of a full-spectrum postbiotic intervention in a population where systemic oxidative load is visibly elevated, such as men with chronic low-grade gut symptoms, using sperm count and standard oxidative-stress biomarkers as outcomes. This kind of study has not yet been run. It is the design we believe the field needs, and it is the direction our own work is moving.

XV - The Bottom Line

The microbiome is connected to reproductive tissue health, but the connection runs through the molecules bacteria produce, not the bacteria themselves. The probiotic-on-the-shelf approach to that connection has been too noisy to deliver reliably, and one of its most-cited recent trials has just been retracted. The FASEB authors call for network-based interventions that restore barrier integrity, microbial balance, and immune resolution together. The mechanism beneath that call is the metabolite layer: short-chain fatty acids, modified bile acids, indoles, and the other bacterial outputs that activate the body's own antioxidant defense systems through pathways like Nrf2 and ARE.

Sperm count, in this story, is one measurable proxy for systemic oxidative stress. The biology that protects reproductive cells is the same biology that protects everything else. Supporting it looks less like supplementing a single strain and more like supporting the whole network: diet diversity, sleep, limiting oxidative stress amplifiers, and watching the postbiotic field as the next decade of mechanistic evidence accumulates.